Die vorliegende Erfindung umfasst Verbindungen der allgemeinen Formel (1) worin R1, R2, R4, Rg, X, m, n und p wie in Anspruch 1 definiert sind, welche zur Behandlung von Krankheiten, die durch exzessive oder anomale Zellproliferation charakterisiert sind, geeignet sind, sowie deren Verwendung zur Herstellung eines Arzneimittels mit den vorstehend genannten Eigenschaften.2,4-Diamino pyrimidine compounds (I) and their tautomers, racemates, enantiomers and/or diastereomers, and optionally their acid addition salts, are new. 2,4-Diamino pyrimidine compounds of formula (I) and their tautomers, racemates, enantiomers and/or diastereomers, and optionally their acid addition salts, are new. X : N or CH； R 1>；3-10C cycloalkyl (substituted with R 3>； and optionally with one or more R 4>；)； R 2>；H, halo, -CN, -NO 2, 1-4C (halo)alkyl, 3-10C cycloalkyl, 4-16C cycloalkylalkyl or 7-16C arylalkyl； R 3>；-C(O)Rc, -C(O)ORC, -C(O)NRCRC, -S(O)2RC, -N(Rf)S(O)2Rc, -N(Rf)C(O)Rc, -N(Rf)C(O)ORc or -N(Rf)C(O)NRcRc； R 4>；Ra or Rb (where Ra is substituted by Rc and/or Rb)； Ra : 1-6C alkyl, 3-10C cycloalkyl, 4-16C cycloalkylalkyl, 6-10C aryl, 7-16C arylalkyl, 2-6 membered heteroalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkylalkyl, 5-12 membered heteroaryl or 6-18 membered heteroarylalkyl； Rb : O=, -ORc, 1-3C haloalkyloxy, -OCF 3, =S, -SRc, =NRc, =NORc, -NRcRc, halo, -CF 3, -CN, -NC, -OCN, -SCN, -NO 2, -S(O)Rc, -S(O) 2Rc, -S(O) 2ORc, -S(O)NRcRc, -S(O) 2NRcRc, -OS(O)Rc, -OS(O) 2Rc, -OS(O) 2ORc, -OS(O) 2NRcRc, -C(O)Rc, -C(O)ORc, -C(O)NRcRc, -CN(Rf)NRcRc, -CN(OH)Rc, -CN(OH)NRcRc, -OC(O)Rc, -OC(O)ORc, -OC(O)NRcRc, -OCN(Rf)NRcRc, -N(Rf)C(O)Rc, -N(Rf)C(S)Rc, -N(Rf)S(O) 2Rc, -N(Rf)C(O)ORc, -N(Rf)C(O)NRcRc, -[N(Rf)C(O)] 2Rc, -N[C(O)] 2Rc, -N[C(O)] 2ORc, -[N(Rf)C(O)] 2ORc or -N(Rf)CN(Rf)NRcRc； Rc : H or optionally Rd and/or Re substituted 1-6C alkyl, 3-10C cycloalkyl, 4-11C cycloalkylalkyl, 6-10C aryl, 7-16C arylalkyl, 2-6 membered heteroalkyl, 3-8 membered heterocycloalky
